VEGF inhibitors (VEGFi, e.g. pazopanib, sorafenib, sunitinib) [24] and BCR-ABL tyrosine kinase inhibitors [15] are examples of anti-cancer therapies which can cause both direct LV systolic dysfunction and indirect LV dysfunction via coronary artery disease including acute myocardial infarction and hypertension [25]. Here, VEGFA is linked to cancer.